Sören Lehmann

This study defines AML cell states through single-cell transcriptomics and links them to drug response and microenvironmental interactions, identifying state-specific vulnerabilities and resistance mechanisms.

This study identifies 16 AML subgroups based on chromatin accessibility profiles using ATAC-seq in 1,563 cases, revealing epigenetic heterogeneity and its clinical and therapeutic implications.

This paper introduces DIPx, a model predicting drug synergy using pathway activation scores, showing better performance than existing methods on both known and novel drug combinations.

This study uses single-cell RNA sequencing to identify novel NPM1 subtypes in AML with distinct clinical outcomes and immune evasion properties.